Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PXS 4728

Next Previous
X
Search
Drug Profile

PXS 4728

Alternative Names: BI 1467335; PXS 4728A; PXS-4728

Latest Information Update: 13 Dec 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmaxis
  • Developer Boehringer Ingelheim; Syntara Limited; University of Oxford; University of Sydney
  • Class Anti-inflammatories; Antiasthmatics; Antifibrotics; Eye disorder therapies; Hepatoprotectants; Small molecules
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II REM-sleep-behavior-disorder
  • No development reported Renal fibrosis
  • Discontinued Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis; Diabetic retinopathy; Non-alcoholic steatohepatitis

Most Recent Events

  • 04 Dec 2023 Pharmaxis is now called Syntara Limited
  • 21 Nov 2023 CTP Push700356599: No updates as info already covered
  • 08 Nov 2023 Phase-II clinical trials in REM sleep behavior disorder (In adults, In the elderly) in Australia (PO) (NCT05904717)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top